Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells <i>In Vitro</i>
作者:Magdalena Slusarczyk、Michaela Serpi、Essam Ghazaly、Benson M. Kariuki、Christopher McGuigan、Chris Pepper
DOI:10.1021/acs.jmedchem.0c02194
日期:2021.6.24
A 3′-protected route toward the synthesis of the diastereomers of clinically active ProTides, NUC-1031 and NUC-3373, is described. The in vitro cytotoxic activities of the individual diastereomers were found to be similar to their diastereomeric mixtures. In the KG1a cell line, NUC-1031 and NUC-3373 have preferential cytotoxic effects on leukemic stem cells (LSCs). These effects were not diastereomer-specific
描述了合成具有临床活性的 ProTides、NUC-1031 和 NUC-3373 的非对映异构体的 3' 保护途径。在体外发现单个非对映体的细胞毒活性与其非对映体混合物相似。在 KG1a 细胞系中,NUC-1031 和 NUC-3373 对白血病干细胞 (LSC) 具有优先的细胞毒作用。这些作用不是非对映异构体特异性的,并且分别用亲本核苷类似物吉西他滨和 FUDR 未观察到。此外,NUC-1031 优先靶向原发性 AML 样本中的 LSC 和前列腺癌细胞系 LNCaP 中的癌症干细胞。尽管其机制仍未完全解决,但 NUC-1031 处理的细胞在 LSC 和大块肿瘤部分中显示出三磷酸水平增加。由于 ProTides 不依赖于核苷转运蛋白,因此 ProTides 观察到的 LSC 靶向似乎可能是由,至少部分引起,